4//SEC Filing
Ege David S. 4
Accession 0000899243-23-011945
CIK 0001609809other
Filed
Apr 30, 8:00 PM ET
Accepted
May 1, 4:46 PM ET
Size
7.6 KB
Accession
0000899243-23-011945
Insider Transaction Report
Form 4
Ege David S.
See Remarks
Transactions
- Sale
Common stock
2023-04-28$5.19/sh−7,038$36,527→ 59,696 total - Award
Common stock
2023-04-27+20,000→ 66,734 total
Footnotes (3)
- [F1]On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 3, 2021, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0350 to $5.1900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001829360
Filing Metadata
- Form type
- 4
- Filed
- Apr 30, 8:00 PM ET
- Accepted
- May 1, 4:46 PM ET
- Size
- 7.6 KB